Stereotactic Body Radiation Therapy to Extend Systemic Therapy Benefit in Patients With Solitary Breast Cancer Progression

What this Trial Is About

Researchers are evaluating whether using Stereotactic Body Radiation Therapy (SBRT) to treat a single metastatic site where breast cancer has worsened may be an effective approach for people with oligometastatic breast cancer. Participants will continue their usual drug therapy while receiving SBRT. This combination is being studied to see if it can prevent the cancer from worsening at other sites or spreading further. Participants with oligometastatic breast cancer who have isolated progression after at least 6 months of response to systemic therapy will receive image-guided SBRT targeted at the progressive lesion seen on imaging. SBRT dosing follows standard department protocols for oligometastatic disease, typically 10 Gy for 3 fractions or 7-8 Gy for 5 daily fractions excluding weekends and holidays. Systemic therapy will be paused during radiation days and resumed afterward. During the study, participants will be monitored for progression-free survival starting from the beginning of SBRT treatment, with assessments at 3 months. Researchers will evaluate the effect of adding SBRT to ongoing drug therapy on cancer progression. Participants will undergo regular imaging and clinical evaluation while continuing their usual care. The total duration of participation varies based on individual treatment schedules and follow-up assessments.

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer